Replies to post #102553 on Biotech Values

[Mpower]

Even if one subscribes to the belief that TEVA is close to obtaining mL approval (which IMHO is not likely), there is a strong argument to be made that the FDA will refrain from acting on the other outstanding applications (TEVA/Amphastar mL applications), until the Sanofi v. FDA case winds down. (i.e. Goes to trial and appeals are exhausted) That could take several months.

[flatlander_60048]

Lighten up!

My point is that the market is extremely skittish right now and the ultimate pop that some of the anxious types want to see may be months or years away since they are other variables that need to play out.

I've been long both NVS and MNTA for years, so the experience has taught me to not swing to euphoria with every positive development. I may lose a few shares if my call options get exercised but I still have a long term core in MNTA.

I think that MNTA would be well served if in the near future they draw attention to their platform, their pipeline and how the FDA decision and bolster future prospects. They are now squarely in the spotlight with a great chance to emphasize future growth prospects.

In the mean time, you might want to limit your caffine intake.

FL

[dewophile]

mnta

You presumably don't believe management's commentary regarding 35-40% market penetration

i was under the impression MNTA management stated they were prepared at launch to cover 35-40% of the market, not that they achieved penetration of 35-40% of the market